Norovirus Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19, 2019-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 19, 2019 Category: Pharmaceuticals Source Type: clinical trials

Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE) July 12, 2018 --Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 12, 2018 Category: Pharmaceuticals Source Type: clinical trials

Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus
Condition: Gastroenteritis Norovirus Interventions: Drug: Nitazoxanide; Other: Placebo Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2018 Category: Research Source Type: clinical trials